Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting investor.lilly.com
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis investor.lilly.com
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem investor.lilly.com
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease investor.lilly.com
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer investor.lilly.com
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas investor.lilly.com
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes investor.lilly.com
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial investor.lilly.com
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine investor.lilly.com
